Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 298 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lactose Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Drugs on Responses to Brain and Emotional Processes

NCT04053036
View directory record Official record
Conditions
Autism Spectrum Disorder, Healthy
Interventions
MDMA, Placebo oral tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Results available

Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana

NCT01844687
View directory record Official record
Conditions
Smoking, Marijuana
Interventions
CBD
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Lexington, Kentucky • New York, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Study of Donepezil in Fragile X Syndrome

NCT01120626
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
donepezil, sugar pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 4, 2026, 10:20 AM EDT
Not listed Not applicable Interventional

SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis

NCT04398550
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Specific Carbohydrate Diet, Mediterranean Diet
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 4, 2026, 10:20 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing the Inflammation, Maldigestion and Symptoms Due to Commercial Milk and A2 Milk

NCT05660278
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Milk containing A1 and A2 beta-casein, Milk containing only A2 beta-casein
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

NCT01404754
View directory record Official record
Conditions
Psychological Effects of Study Drug
Interventions
Lactose (inactive placebo), midomafetamine HCl
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
3
States / cities
Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 4, 2026, 10:20 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

NCT01174056
View directory record Official record
Conditions
Lung Inflammation
Interventions
Zileuton, Pioglitazone placebo, Zileuton placebo, Pioglitazone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 4, 2026, 10:20 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

NCT01986777
View directory record Official record
Conditions
Cognitive Impairments, RRSO
Interventions
lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00603265
View directory record Official record
Conditions
Peripheral Neuropathy, Neuropathic Pain
Interventions
ADL5859, Duloxetine, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Riverside, California • Torrance, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 4, 2026, 10:20 AM EDT
Withdrawn Not applicable Interventional

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

NCT01695707
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pioglitazone, Placebo (for pioglitazone)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 4, 2026, 10:20 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

NCT00587496
View directory record Official record
Conditions
Herpes Simplex
Interventions
valacyclovir hydrochloride, placebo, valacyclovir plus aspirin
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
20 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Sep 4, 2026, 10:20 AM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

NCT02673749
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28, Placebo
Drug · Other
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 4 Interventional Results available

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

NCT02799784
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, TIO/OLO, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 4, 2026, 10:20 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Melatonin and Salt on Blood Vessel Function

NCT04325191
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Melatonin, Placebo
Dietary Supplement · Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 1 Interventional

Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects

NCT00567034
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
naltrexone, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 4, 2026, 10:20 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

NCT01986764
View directory record Official record
Conditions
Planned RRSO
Interventions
Lisdexamfetamine, Estradiol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 48 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 4, 2026, 10:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

NCT05975021
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Istaroxime, Placebo
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 4, 2026, 10:20 AM EDT
Completed Phase 4 Interventional

Naltrexone Treatment of Alcohol Abuse in Schizophrenia

NCT00145847
View directory record Official record
Conditions
Schizophrenia, Mental Disorders, Alcohol Abuse, Alcoholism, Alcohol-related Disorders
Interventions
Naltrexone or Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 4, 2026, 10:20 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Genepro Generation 3 Protein Bioavailability Compared to Whey Protein

NCT04615858
View directory record Official record
Conditions
Absorption; Disorder, Protein, Protein Malabsorption, Protein Intolerance
Interventions
Genepro Generation 3 Protein, Whey Protein
Dietary Supplement
Lead sponsor
Musclegen Research, Inc.
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cary, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 4, 2026, 10:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 4, 2026, 10:20 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Beef Versus Whey Protein: The Gut Showdown Self-Experiment

NCT07477223
View directory record Official record
Conditions
Digestion
Interventions
Beef protein, Chocolate whey protein
Dietary Supplement
Lead sponsor
Efforia, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 4, 2026, 10:20 AM EDT